Forvisirvat
Small molecule
Also known as SP-624
Evidence outlook · results not reported
NCT06254612 · Major Depressive Disorder
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT06254612: This is a large, randomized, fully blinded, placebo-controlled trial using a validated depression rating scale as its primary measure, a well-designed setup for showing a real treatment effect. Because results have not been posted yet, the evidence currently reflects the strength of the design, not a demonstrated outcome.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04479852 NCT04479852 · Major Depressive Disorder The study randomized 319 participants to SP-624 or placebo and used quadruple masking, with 132 SP-624 and 125 placebo participants included in the primary analysis. Its clinical primary endpoint, change in MADRS score at Week 4, was not statistically significant (p=0.133), so the results provide well-controlled but inconclusive evidence of benefit. Registry: NCT04479852 | 2 | Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score 2022-06-27 | Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) | Partial signal | link ↗ |
View 1 more trial
NCT06254612 NCT06254612 · Major Depressive Disorder This is a large, randomized, fully blinded, placebo-controlled trial using a validated depression rating scale as its primary measure, a well-designed setup for showing a real treatment effect. Because results have not been posted yet, the evidence currently reflects the strength of the design, not a demonstrated outcome. Registry: NCT06254612 | 2 | Change from Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. (Baseline to Week 4) 2026-07-08 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other SIRT6 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Major Depressive Disorder: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Forvisirvat: this drug | Phase 2 | Small molecule | SIRT6 | Partial signal | NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6) NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51) | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | Partial signal | NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7) | |
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA, Dopamine/norepinephrine transporter | Partial signal | NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862) NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | not yet graded | No reviewed efficacy summary in this indication | |
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor | Partial signal | NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88) NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed | |
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | Weak signal | NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54) NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53) | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Vortioxetine (Trintellix) | Approved | Small molecule | Serotonin transporter + multiple 5-HT receptors | Partial signal | NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed | |
| Ammoxetine | Phase 3 | Small molecule | Serotonin/norepinephrine transporter | Partial signal | NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27). | |
| Ansofaxine Hydrochloride | Phase 3 | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001). | |
| Azetukalner | Phase 3 | Small molecule | Kv7 potassium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Deupsilocin | Phase 3 | Small molecule | 5-HT2A receptor | Partial signal | NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151) | |
| KH607 | Phase 3 | Small molecule | GABA-A receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Lysergide Tartrate (LSD) (DT120) | Phase 3 | Small molecule | 5-HT2A receptor | Reliable signal | NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. | |
| Milsaperidone (VHX-896) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Osavampator | Phase 3 | Small molecule | AMPA receptor (positive allosteric modulator) | Partial signal | NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082). | |
| Psilocybin (COMP360) | Phase 3 | Small molecule | 5-HT2A receptor | Reliable signal | NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001) | |
| Seltorexant | Phase 3 | Small molecule | Orexin-2 receptor (OX2R) | Partial signal | NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26) NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed | |
| Solriamfetol (Sunosi) | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | Partial signal | NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed | |
| D-Cycloserine / Lurasidone (NRX-101) | Phase 2/3 | Small molecule | NMDA receptor (glycine site) + dopamine/5-HT receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Mitizodone Phosphate | Phase 2/3 | Small molecule | Serotonin transporter/5-HT receptor | Weak signal | No reviewed efficacy summary in this indication | |
| ACP-211 | Phase 2 | Small molecule | NMDA receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | Partial signal | NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33% | |
| ALTO-203 | Phase 2 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Partial signal | No reviewed efficacy summary in this indication | |
| ALTO-300 | Phase 2 | Small molecule | Melatonergic (MT) receptors (agonist) + serotonin receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Arketamine (PRT042) | Phase 2 | Small molecule | NMDA receptor | not yet graded | No reviewed efficacy summary in this indication | |
| AV-101 | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed | |
| BI 1569912 | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed | |
| Blixeprodil | Phase 2 | Small molecule | NMDA receptor | Weak signal | Featured results are safety only in this race | |
| BPL-003 (mebufotenin Benzoate) | Phase 2 | Small molecule | 5-HT2A receptor | Partial signal | NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). | |
| Bretisilocin | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cyclobenzaprine (Tonmya) | Phase 2 | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | not yet graded | No reviewed efficacy summary in this indication | |
| DT-101 | Phase 2 | Small molecule | AMPA receptor (positive allosteric modulator) | not yet graded | No reviewed efficacy summary in this indication | |
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Emestedastat (Xanamem) | Phase 2 | Small molecule | 11-beta-HSD1 | Partial signal | NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed | |
| Esketamine (CLE-100) | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed | |
| Evifacotrep | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2 | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| GW117 | Phase 2 | Small molecule | Melatonin MT1/MT2 receptor + 5-HT2C receptor | Partial signal | NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed | |
| HS-10353 | Phase 2 | Small molecule | GABA-A receptor | Weak signal | NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses | |
| Hypidone (YL-0919) | Phase 2 | Small molecule | Serotonin transporter/5-HT1A receptor/sigma-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-89495120 | Phase 2 | Small molecule | Muscarinic M1 receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Liafensine | Phase 2 | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31) NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed | |
| LV232 | Phase 2 | Small molecule | Serotonin transporter + 5-HT3 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Mebufotenin (5-MeO-DMT) (GH001) | Phase 2 | Small molecule | 5-HT2A receptor | Partial signal | NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001) | |
| Nelivaptan | Phase 2 | Small molecule | Vasopressin V1B receptor | Partial signal | NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo. | |
| NH102 | Phase 2 | Small molecule | Serotonin/norepinephrine/dopamine transporter + 5-HT2A receptor | Partial signal | No reviewed efficacy summary in this indication | |
| PDC-1421 | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | Partial signal | NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61) | |
| Pramipexole / Ondansetron (ALTO-207) | Phase 2 | Small molecule | Dopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Ropanicant | Phase 2 | Small molecule | Alpha4beta2 nicotinic acetylcholine receptor | Partial signal | NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met. NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1. | |
| SPN-820 | Phase 2 | Small molecule | mTORC1 | Partial signal | NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed | |
| SPN-821 | Phase 2 | Small molecule | mTORC1 (mammalian target of rapamycin complex 1) (activator) | not yet graded | No reviewed efficacy summary in this indication | |
| VLS-01 | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Zelquistinel | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed | |
| ELE-101 | Phase 1/2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALA-3000 | Phase 1 | Small molecule | NMDA receptor | Partial signal | Featured results are safety only in this race | |
| Apimostinel | Phase 1 | Small molecule | NMDAR agonist/modulator | Weak signal | Featured results are safety only in this race | |
| IMU-856 | —(overall) | Small molecule | SIRT6 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Large race: only the 61 furthest-along competitors are listed; 9 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.